Amicus Therapeutics sees current cash to fund operations into 2017 Amicus Therapeutics provided its full-year 2015 strategic outlook and financial guidance. The company sees its FY15 net cash spend expected to range between $73M-$83M. Current cash of $169.1M at December 31, 2014 is projected to fund operating plan into 2017. Amicus said migalastat monotherapy FDA interaction is planned in 1Q15 and an MAA submission is on track for mid-2015 to seek marketing approval for Fabry patients with amenable mutations. Initiation of longer-term Phase 2 Fabry co-administration study is anticipated in 2015 in support of Fabry franchise strategy to develop migalastat in combination with ERT for Fabry patients with non-amenable mutations. Next-generation Pompe ERT is set to enter clinic in 2H15 and additional details on Pompe program are to be highlighted at 33rd Annual J.P. Morgan Healthcare Conference, the company said.